Current Hepatology Reports

, Volume 17, Issue 2, pp 97–104 | Cite as

The Newest Direct-Acting Antiviral Agents: the Final Chapter in DAA Development

  • Marwa Ismail
  • Jordan J. Feld
Hepatitis C (A Aronsohn and H Vargas, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Hepatitis C


Purpose of the Review

Hepatitis C virus (HCV) therapy has improved dramatically in recent years; however, small clinical gaps remained. The recent approval of the final two antiviral regimens likely to come to clinical use addresses most unmet medical needs. The clinical trial data supporting the approval of these regimens is reviewed, highlighting how they address outstanding clinical needs and noting the very few gaps that still remain.

Recent Findings

The approval of sofosbuvir/velpatasvir/voxilaprevir provides an excellent salvage regimen for patients who have failed prior treatment with direct antiviral agents. A 12-week course of therapy leads to sustained virological response in almost all retreatment settings. In addition, the approval of glecaprevir/pibrentasvir offers an 8-week treatment option for all non-cirrhotic treatment-naïve patients and also provides a much needed therapy for patients with chronic kidney disease and HCV genotypes other than 1 and 4.


Two newly approved regimens have been approved for HCV patients who previously failed direct antiviral therapy and patients with chronic kidney disease with genotypes other than 1 and 4.


Hepatitis C virus (HCV) Direct-acting antiviral (DAA) Retreatment Renal impairment Chronic kidney disease Short-therapy 


Compliance with Ethical Standards

Conflict of Interest

Marwa Ismail declares no conflicts of interest.

Jordan J. Feld reports grants and personal fees from AbbVie, Gilead, Merck, Janssen, personal fees from Contravir, and grants from Abbott, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62(1 Suppl):S87–99.CrossRefPubMedGoogle Scholar
  2. 2.
    Feld JJ, Foster GR. Second generation direct-acting antivirals—do we expect major improvements? J Hepatol. 2016;65(1 Suppl):S130–42.CrossRefPubMedGoogle Scholar
  3. 3.
    Feld JJ, Maan R, Zeuzem S, Kuo A, Nelson DR, Di Bisceglie AM, et al. Effectiveness and safety of sofosbuvir-based regimens for chronic HCV genotype 3 infection: results of the HCV-TARGET study. Clin Infect Dis. 2016;63(6):776–83.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    • Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131–1140 e1135. Key study showing real-world data with highly effective HCV regimens CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, Park JS, Landis CS, Hassan M, Gallant J et al Safety and effectiveness of ledipasvir and sofosbuvir, with or without ribavirin, in treatment-experienced patients with genotype 1 hepatitis C virus infection and cirrhosis. Clin Gastroenterol Hepatol 2018.Google Scholar
  6. 6.
    Cacoub P, Desbois AC, Isnard-Bagnis C, Rocatello D, Ferri C. Hepatitis C virus infection and chronic kidney disease: time for reappraisal. J Hepatol. 2016;65(1 Suppl):S82–94.CrossRefPubMedGoogle Scholar
  7. 7.
    Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537–45.CrossRefPubMedGoogle Scholar
  8. 8.
    Sise ME, Backman E, Ortiz GA, Hundemer GL, Ufere NN, Chute DF, et al. Effect of sofosbuvir-based hepatitis C virus therapy on kidney function in patients with CKD. Clin J Am Soc Nephrol CJASN. 2017;12(10):1615–23.CrossRefPubMedGoogle Scholar
  9. 9.
    Li T, Qu Y, Guo Y, Wang Y, Wang L. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. Liver Int. 2017;37(7):974–81.CrossRefPubMedGoogle Scholar
  10. 10.
    Maan R, Al Marzooqi SH, Klair JS, Karkada J, Cerocchi O, Kowgier M, et al. The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens. Aliment Pharmacol Ther. 2017;46(1):46–55.CrossRefPubMedGoogle Scholar
  11. 11.
    Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min. Liver Int. 2016;36(6):798–801.CrossRefPubMedGoogle Scholar
  12. 12.
    Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–76.Google Scholar
  13. 13.
    van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernandez-Rodriguez CM, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017;66(3):485–93.CrossRefPubMedGoogle Scholar
  14. 14.
    Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127–35.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology. 2016;63(5):1430–41.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hezode C, Lebray P, De Ledinghen V, Zoulim F, Di Martino V, Boyer N, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. Liver Int. 2017;37(9):1314–24.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    •• Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608–17. Pivotal trial demonstrating the very high efficacy of sofosobvuir and velpatasvir for the more ‘difficult-to-cure’ genotype 3 infection CrossRefPubMedGoogle Scholar
  18. 18.
    • Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–28. Key study demonstrating the importance of ribavirin in treating patients with decompensated cirrhosis CrossRefPubMedGoogle Scholar
  19. 19.
    AASLD/IDSA: Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. (Accessed 11 Dec 2017) 2017.
  20. 20.
    Kondili LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, et al. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: interim evaluations from the PITER network. PLoS One. 2017;12(10):e0185728.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88.CrossRefPubMedGoogle Scholar
  22. 22.
    •• Bourliere M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134–46. Critical study highlighting the efficacy of sofosbuvir/velpatasvir/voxilaprevir as a salvage regimen for people who have not responded to first-line DAA therapy CrossRefPubMedGoogle Scholar
  23. 23.
    Struble K, Chan-Tack K, Qi K, Naeger LK, Birnkrant D Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration’s evaluation. Hepatology 2017.Google Scholar
  24. 24.
    Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017;66(5):910–8.CrossRefPubMedGoogle Scholar
  25. 25.
    • Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153(1):113–22. Important study showing that this triple combination can be used effectively for 8 weeks in some but not all genotypes. The fact that it was not as effective as 12 weeks for genotype 1a led to its approval primarily as a salvage regimen in North America CrossRefPubMedGoogle Scholar
  26. 26.
    •• Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354–69. Important demonstration of the efficacy of glecaprevir/pibrentasvir when given for only 8 weeks in patients with genotype 1 and 3 infection without cirrhosis, providing the first 8-week regimen without restrictions for non-cirrhotic patients CrossRefPubMedGoogle Scholar
  27. 27.
    Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V et al Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 2017.Google Scholar
  28. 28.
    • Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17(10):1062–8. Key study demonstrating the efficacy and safety of glecaprevir/pibrentasvir in patients with compenstaed cirrhosis CrossRefPubMedGoogle Scholar
  29. 29.
    Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, Maliakkal B, Agarwal K, Hassanein T, Weilert F et al Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase 3 clinical trial. Hepatology 2017.Google Scholar
  30. 30.
    Wyles D, Poordad F, Wang S, Alric L, F F, Kwo P, Maliakkal B, Agarwal K, Hassanein T, Weilert F et al SURVEYOR-II, Part 3: efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or cirrhosis Hepatology 2016, AASLD The Liver Meeting 2016.Google Scholar
  31. 31.
    •• Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Brau N, Brown A, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377(15):1448–55. Critical study highlighting that this combination is safe and effective in patients with advanced kidney disease, offering a regimen for patients with genotypes other than 1 and 4 HCV CrossRefPubMedGoogle Scholar
  32. 32.
    Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hezode C, et al. Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology. 2017;Google Scholar
  33. 33.
    Vosevi Product Insert. 2017.Google Scholar
  34. 34.
    Mavyret Product Insert. 2017.Google Scholar
  35. 35.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Toronto Centre for Liver Disease, Sandra Rotman Centre for Global HealthUniversity of TorontoTorontoCanada
  2. 2.Toronto General HospitalTorontoCanada

Personalised recommendations